Johnson & Johnson
JNJ- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000200406
In the last 90 days, Johnson & Johnson insiders filed 0 open-market purchases and 6 sales; 4,699 institutions reported holding it in 13F filings for Q2 2026, worth $456.9B in total; 5 superinvestors hold it, including Markel Group and Fairfax Financial.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Johnson & Johnson insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 5 insiders, $67.8M in total
- Insiders trading
- 5
- Net value
- −$67.8M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Johnson & Johnson, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pinto Daniel E | Director | – | Sep 10, 2026 | 5 |
| Woods Eugene A. | Director | – | Sep 10, 2026 | 5 |
| Hewson Marillyn A | Director | – | Sep 10, 2026 | 5 |
| Schmid Timothy | EVP, WW Chair, MedTech | 25,447 | Sep 4, 2026 | 5 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 194,451 | Aug 18, 2026 | 3 |
| Duato Joaquin | CEO and Chairman of the Board | 275,967 | Aug 14, 2026 | 5 |
| Forminard Elizabeth | EVP, Chief Legal Officer | 16,994 | Aug 7, 2026 | 4 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | 23,003 | Jul 21, 2026 | 3 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | 114,288 | Jun 12, 2026 | 4 |
| Reed John C | EVP, Innovative Medicine, R&D | 24,911 | May 4, 2026 | 3 |
| Morikis John G | Director | 1,849 | Apr 27, 2026 | 2 |
| Johnson Paula A | Director | – | Apr 27, 2026 | 1 |
| Joly Hubert | Director | – | Apr 27, 2026 | 1 |
| Beckerle Mary C | Director | – | Apr 27, 2026 | 1 |
| McClellan Mark B. | Director | – | Apr 27, 2026 | 1 |
| Doudna Jennifer A | Director | – | Apr 27, 2026 | 1 |
| Weinberger Mark A | Director | 1,000 | Apr 27, 2026 | 1 |
| West Nadja | Director | – | Apr 27, 2026 | 1 |
| Decker Robert J | VP Corporate Controller | 23,682 | Mar 3, 2026 | 3 |
| Wolk Joseph J | Exec VP, CFO | 14,000 | Feb 18, 2026 | 2 |
| Swanson James D. | EVP, CIO | 25,698 | Feb 18, 2026 | 2 |
| Mulholland Kristen | EVP, Chief HR Officer | 19,830 | Feb 18, 2026 | 3 |
| Davis D Scott | Director | – | Oct 15, 2024 | 0 |
| Mulcahy Anne M | Director | – | Apr 29, 2024 | 0 |
| Adamczyk Darius | Director | – | Apr 29, 2024 | 0 |
| Fasolo Peter | Exec VP, Chief HR Officer | 112,076 | Feb 20, 2024 | 0 |
| Hait William | EVP, Chief EI and Med Officer | 38,647 | Feb 20, 2024 | 0 |
| McEvoy Ashley | EVP, WW Chair, MedTech | 52,038 | Aug 25, 2023 | 0 |
| Washington A. Eugene | Director | – | Mar 9, 2023 | 0 |
| Mongon Thibaut | Exec VP, WW Chair, Cons Health | 65,915 | Feb 15, 2023 | 0 |
| Gorsky Alex | Director | 766,584 | Jan 18, 2023 | 0 |
| Williams Ronald A | Director | – | Feb 17, 2022 | 0 |
| Prince Charles | Director | – | Feb 17, 2022 | 0 |
| Mammen Mathai | EVP, Pharm, R&D | 41,934 | Feb 17, 2022 | 0 |
| Davis Ian | Director | – | Feb 17, 2022 | 0 |
| Ullmann Michael H | Exec VP, General Counsel | 158,835 | Feb 17, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2026 (view filing)5:27 PM ET | Jul 20 | 1 day | Broadhurst VanessaEVP, Global Corp Affairs | SSale | −23.1K | $251.27 | −$5.79M | −50.1%23.0K after | |
| Aug 7, 2026 (view filing)5:44 PM ET | Aug 6 | 1 day | Forminard ElizabethEVP, Chief Legal Officer | SSale | −15.9K | $257.00 | −$4.09M | −48.4%17.0K after | 2 lots |
| Aug 7, 2026 (view filing)5:50 PM ET | Aug 5 | 2 days | Duato JoaquinCEO and Chairman of the Board | SSale | −48.5K | $258.15 | −$12.5M | −14.9%276.0K after | 2 lots |
| Aug 14, 2026 (view filing)4:35 PM ET | Aug 13 | 1 day | Duato JoaquinCEO and Chairman of the Board | SSale | −123.3K | $261.17 | −$32.2M | −30.9%276.0K after | 2 lots |
| Aug 18, 2026 (view filing)6:31 PM ET | Aug 17 | 1 day | Taubert Jennifer LEVP, WWC. Innovative Medicine | SSale | −15.0K | $263.36 | −$3.95M | −7.2%194.5K after | |
| Sep 4, 2026 (view filing)9:08 AM ET | Sep 2 | 2 days | Schmid TimothyEVP, WW Chair, MedTech | SSale | −33.6K | $274.74 | −$9.23M | −56.9%25.4K after | 2 lots |